SCHEMBL6682745

SCHEMBL6682745

CCC(C)c1ccc(N(C/C=C/c2ccccc2)C(=N)N)cc1

nearest known ligand 0.50

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.38
CYP2C9 P11712 1/20 0.37
CNR2 P34972 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4984316 0.99 HTR2A (0.38) HTR2ACYP2C9
SCHEMBL4981814 0.78 GRIN2D (0.40) CNR2
SCHEMBL6547448 0.72 RELA (0.48) HTR2ACYP2C9
SCHEMBL14570387 0.71 RELA (0.46) CYP2C9CNR2
SCHEMBL13475128 0.71 RELA (0.46) CYP2C9CNR2
SCHEMBL4979723 0.70 CYP2C9 (0.41) CYP2C9
SCHEMBL5448297 0.69 ALOX5 (0.51)
SCHEMBL4983301 0.69 MME (0.41)
SCHEMBL12292333 0.67 CYP2C9 (0.49) CYP2C9
SCHEMBL14570389 0.67 TRPM8 (0.45) CYP2C9CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004072255-A2 METHODS OF TREATING DISEASE SCION PHARMACEUTICALS, INC. (US) 2004-08-26 WO disclosed
EP-0751767-A4 THERAPEUTIC GUANIDINES CAMBRIDGE NEUROSCIENCE INC (US) 1997-12-10 EP disclosed
EP-0751767-A1 THERAPEUTIC GUANIDINES CAMBRIDGE NEUROSCIENCE, INC. (US) 1997-01-08 EP disclosed
WO-1995020950-A1 THERAPEUTIC GUANIDINES CAMBRIDGE NEUROSCIENCE, INC. (US) 1995-08-10 WO disclosed